Summary:
Purpose: To quantify the risks of intrauterine an tiepileptic drug (AED) exposure in monotherapy and polytherapy.
Methods: Data from five prospective European studies total ing 1,379 children were pooled and reanalyzed. Data were available for 1,221 children exposed to AED during pregnancy and for 158 children of unexposed control pregnancies.
Results: Overall, when comparing a subgroup of 192 children exposed to AED with 158 children of matched nonepileptic controls, there was an increased risk of major congenital mal formations (MCA) in children exposed to AED during gesta tion [relative risk (RR) 2.3; 95% confidence interval (Cl): 1. 2-4.7] . A significant increase in risk was found for children ex posed to valproate (VPA) (RR 4.9; 95% Cl: 1.6-15,0) or carbamazepine (CBZ) (RR 4.9; 95% Cl: 1,3-18.0) in mono therapy. When comparing different AED regimens during all 1,221 pregnancies, risks of MCA were significantly increased for the combination of phenobarbital (PB) and ethosuximide (RR 9.8; 95% Cl: 1.4-67,3) and the combination of phenytoin, PB, CBZ, and VPA (RR 11.0; 95% Cl: 2.1-57.6). Offspring of mothers using >1,000 mg VP A/day were at a significantly in creased risk of MCA, especially neural tube defects, compared to offspring exposed ^600 mg VP A/day (RR 6.8; 95% Cl: 1. 4-32.7) . No difference in risk of MCA was found between the offspring exposed to 601-1,000 mg/day and ^600 mg/day.
Conclusions: This reanalysis shows that VPA is consistently associated with an increased risk of MCA in babies born to mothers with epilepsy. Significant associations were also ob served with CBZ. Larger prospective population-based studies are needed to evaluate the risks of many other less frequently prescribed treatment regimens, including newly marketed AEDs. Key Words: Antiepileptic drugs-Major congenital malformations-Pregnancy-Epileptic offspring.
Maternal use of antiepileptic drugs (AEDs) during pregnancy has been associated with an increased risk of major congenital abnormalities (MCA) in the fetus. Yet in many women planning a pregnancy antiepileptic drugs cannot be discontinued because of the risk of seizures during pregnancy, which can be harmful to both mother and child (1) (2) (3) . Furthermore, acute discontinuation dur ing early pregnancy is also not recommended because of the risk of increased numbers of seizures and status epi-lepticus (4) (5) (6) . Many children of women with epilepsy are therefore at a two-to threefold increased risk of congenital malformations as compared with the general population (7) (8) (9) (10) (11) (12) (13) (14) and an important clinical issue is how to treat women with epilepsy during pregnancy (15) (16) (17) (18) .
Many questions concerning risks associated with the specific AEDs are unanswered. In the studies conducted to date, no specific drug regimen has consistently shown a lower risk than any other, suggesting that AED therapy is implicitly related to an increased risk of congenital malformations. However, in most of these studies, the number of pregnancies was relatively small (19) (20) (21) (22) (23) , which limits the possibilities for detecting potential
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dose-response relationships. Furthermore, studies may differ in regard to both definitions and procedures. In a collaborative analysis, these factors can be taken into account by increasing the number of subjects, application of standardized definitions, and evaluation of effects that are consistent across studies.
Therefore, to quantify the specific risks of AEDs in m onotherapy and polytherapy, we reanalyzed data pooled from five prospective European studies. The pre sent study focuses on pregnancies in women with epi lepsy treated with AEDs* The first aim was to assess the risk of MCA of children exposed in utero to AEDs dur ing pregnancy as compared with the risk of children not exposed to AEDs. The second aim was to quantify risks of MCA associated with specific AED regimens.
METHODS
For the present study, raw data from five studies were pooled. These studies included were prospective studies conducted in Europe from 1971 to 1990. The studies were selected on the basis of their prospective design and before knowing the outcome to minimize selection bias. One study was conducted in Helsinki, Finland; 2 studies were conducted in Germany, 1 in Berlin (former West Berlin) and 1 in Magdeburg; and 2 were conducted in The Netherlands, 1 in the South West Netherlands, in cluding, the municipality of Rotterdam, and 1 in the out patient clinics of the Dutch Special Centres for Epilepsy. Included in the studies were 896 women with epilepsy treated with AEDs and 1,221 children born to these sub jects, and 158 children born to nonepileptic control sub jects (Table 1) . Of the AED-treated women, 326 (36%) had generalized epilepsy, 484 (54%) had localizationrelated epilepsy, and 28 (3%) had unclassified epilepsy; in 58 (1%) women, the type of epilepsy was unknown. The assessment of seizures during pregnancy, especially in the first trimester, was incomplete and varied among study groups with respect to assessment procedures and definition. Therefore, adequate and comparable data on seizure frequency were not available for reanalysis.
Individual studies
During the 1981 workshop in Berlin on Epilepsy, Pregnancy, and the Child, participating groups compared their prospective study designs and concluded that the different studies were adequately comparable and there fore suitable for a collaborative analysis, once the indi vidual studies had been published. All were designed as prospective studies of the reproductive outcome of preg Years of study 1979-1990 1979-1987 1976-1979 1985-1990 1972-1990 No. of AED-exposed  150  42  106  305  618  pregnancies  No. of nonepileptic  116 42 nancies of women with epilepsy. The studies recruited all consecutive pregnant women with epilepsy. These stud ies conducted in Berlin and Magdeburg also included nonepileptic control pregnancies. During the 1985 Inter national Epilepsy Symposium held in Hamburg, Ger many, a collaborative analysis of the data from these centers was agreed upon and a grant application was approved by the International League Against Epilepsy and forwarded to the Klingenstein foundation. The com parability of case ascertainment and the assessment of MCA in the individual studies were evaluated in visits to the study centers and discussions of the individual pro tocols. The study design, in particular the selection of the exposed and nonexposed pregnancies used in this analy sis, is described individually for each study herein. The studies are ordered alphabetically by city and country.
Berlin, Germany
The Berlin study was conducted between 1979 and 1990 (24) . The study comprised 123 mothers with epi lepsy. Included were 150 AED-exposed pregnancies ( Table 1 ). Only patients whose epilepsy diagnosis was confirmed by a neurologist and in whom the first seizure occurred before pregnancy were included. Of the cohort, 80% were ascertained through 12 obstetric clinics in the area of Berlin and 20% was ascertained through the neu rology department at the former University Hospital Charlottenburg. Control pregnancies (n = 116) were se lected through the obstetric clinics, matched for maternal age at delivery, parity, social class, smoking habits, and previous abortions. Patients and controls were recruited during pregnancy before fetal outcome was known. For each pregnancy, data on maternal epilepsy and AED therapy, family history, obstetric history, and smoking, alcohol, and drug abuse were collected. Stillbirths and neonatal deaths were included. At birth and at 1 and 4 years, children underwent physical examination by a pe diatrician according to a standardized protocol. The end points for examination were major and minor malfor mations, including body measurements, occurrence of neural tube defects, cleft lip and palate, skeletal malfor mations, abdominal defects, genitourinary defects, car diac defects, and dysmorphic features.
Helsinki, Finland
The Helsinki study was conducted based on ascertain ment of pregnancies between 1976 and 1979 (25) and comprised 97 mothers with epilepsy. Included were 106 AED-exposed pregnancies (Table 1) . Only patients in whom the epilepsy diagnosis was confirmed by a neu rologist and in whom the first seizure occurred before pregnancy were included. Subjects were recruited during weeks 7-24 of pregnancy; all maternity units were asked to refer patients with epilepsy for the study to the Hel sinki University City Hospital. Patients with premature deliveries (pregnancy duration 16-24 weeks) were ex cluded, but stillbirths/neonatal deaths were not. Data from control pregnancies were not available for this re analysis. For each pregnancy, data on maternal epilepsy and AED treatment, family history, obstetric history, and smoking habits were collected. At birth and at 1.5 and 5.5 years of age, each child was examined by a pediatric neurologist according to a standardized protocol (26) . The endpoints for examination were major and minor malformation, including body measurements, occurrence of neural tube defects, cleft lip and palate, skeletal mal formations, abdominal defects, genitourinary defects, cardiac defects, and dysmorphic features.
Magdeburg, Germany
Pregnancies were ascertained between 1979 and 1987 according to a protocol similar to that of the Berlin study (27, 28) . There were 32 mothers with epilepsy and 42 AED-exposed pregnancies ( Table 1 ). The diagnosis of epilepsy was always confirmed by a neurologist. In all but 4 patients, the first seizure occurred before preg nancy. Patients were referred to the coordinating pediat ric neurologist by two obstetric departments. The next delivery after birth of the exposed infant was selected as a control pregnancy (n = 42). The matching criteria were sex, obstetric clinic, maternal age at delivery, par ity, social class, smoking habits, and previous abortions. Women with a positive family history of epilepsy were excluded as controls. Subjects were recruited during pregnancy. Patients and controls with stillbirths and neo natal deaths were excluded, since the primary endpoint of the study was postnatal development. Data on mater nal epilepsy and AED therapy, family history, obstetric history, and smoking, alcohol, and drug abuse were col lected. At birth and at 1.5 and 5 years, physical exami nation was performed by a pediatrician according to a standardized protocol. The endpoints for examination were major and minor malformations, including body measurements, occurrence of neural tube defects, cleft lip and palate, skeletal malformations, abdominal de fects, genitourinary defects, cardiac defects, and dysmor phic features.
Rotterdam, The Netherlands
The Rotterdam study was conducted from 1985 to 1990 and comprised 261 women with epilepsy (23, (29) (30) (31) consecutively referred to the outpatient clinic for prenatal diagnosis of the University Hospital Rotterdam, because of epilepsy with AED (or without AED) treat ment. Subjects were recruited before month 4 of preg nancy. Only patients whose epilepsy diagnosis was con firmed by a neurologist were included. Data were avail able on 305 AED-exposed pregnancies (Table 1) . Either amniocentesis or structural ultrasound (and in most pa tients, both) was performed. Some pregnancies were in terrupted because of MCA discovered during prenatal testing. These pregnancies were included in the study.
No control pregnancies are available. Data on maternal epilepsy and AED therapy, family history, obstetric his tory, and smoking, alcohol, and drug abuse were col lected. Pregnancies ending in stillbirth or neonatal death were included. Neonatal examination was performed by a gynecologist or pediatrician, and defects observed in the first 3 months of life were included. The main end points were MCA, including body measurements, occur rence of neural tube defects, cleft lip and palate, skeletal malformations, abdominal defects, genitourinary defects, cardiac defects, and dysmorphic features.
Institutes of Epilepsy, The Netherlands
The Institutes of Epilepsy cohort consisted of 411 women with epilepsy derived from 1 of 14 outpatient clinics of the Special Centres for Epilepsy in The Neth erlands (Instituut voor Epilepsie bestrijding Heemstede, Kempenhaeghe Heeze, and Dr. Hans B erger-kliniek Br eda) from period 1972 to 1990. In these centers, ~7% of all patients with epilepsy in the Netherlands are treated. Included were 618 consecutive AED-exposed pregnan cies ( Table 1 ). The entire cohort was subdivided into three groups (A, B, and C). The first study (cohort A) was conducted between 1972 and 1979 and comprised 151 AED-exposed pregnancies (32) (33) (34) . The second study (cohort B) was conducted between 1980 and 1985 and comprises 172 AED-exposed pregnancies (11) . The remaining pregnancies (cohort C) were collected be tween 1985 and 1990 and consist of 295 AED-exposed pregnancies (not previously published). Diagnosis of epi lepsy was confirmed by a neurologist. No control preg nancies are available. Subjects were recruited during or before pregnancy, and AED exposure was monitored during pregnancy. All abortions, premature deliveries, and stillbirths are included. Data on maternal epilepsy and AED treatment, family history, obstetric history, and smoking, alcohol, and drug abuse were collected by the attending neurologist, and forms were completed at the first visit to the outpatient clinic after delivery (usually 3-5 months after delivery). The neonatal examination was performed by a gynecologist or pediatrician, and MCA discovered within 3 months after birth were used in the analysis. The main endpoints were MCA, includ ing body measurements, occurrence of neural tube de fects, cleft lip and palate, skeletal malformations, ab dominal defects, genitourinary defects, cardiac defects, and dysmorphic features.
Assessment of malformations
For this analysis, we defined M CA as an abnormality of an essential embryonal structure, present at birth or discovered during the first 3 months of life and requiring major intervention before the first year of life. Examples of MCA according to this definition are: neural tube defects, congenital heart defects, hypospadias, cleft lip and palate, pre-and/or postaxial polydactyly, club foot, congenital hip dysplasia requiring plaster therapy, and inguinal hernia, requiring operation.
Data analysis
Raw data from the participating sites were pooled and reanalyzed for the reanalysis. The data were analyzed in two ways. First, the occurrence of MCA associated with maternal epilepsy and AED exposure were compared with the occurrence of MCA in control pregnancies. Be cause the latter were available only for the Berlin and Magdeburg studies, this analysis was limited to those two studies. We performed multiple logistic regression to estimate the relative risk (RR), using all nonepileptic controls as a reference and adjusting for the matching variables by including them in the regression model. RR are presented with a 95% confidence interval (95% Cl), which will exclude the value 1 in case of statistical sig nificance (p < 0.05).
Second, risks associated with specific AED regimens were compared between pregnancies exposed to differ ent regimens. RR were used to quantify the strength of the association and are presented with 95% CI. Multiple logistic regression analysis was used to adjust for puta tive confounding variables such as maternal age, parity, social class, sex of the child, study site, type of epilepsy, and dose of medication. If AEDs were used in sufficient numbers, we tested for the presence of a dose-response relationship, with cutoff points based on tertiles. For this analysis, no data from the Helsinki study were available.
RESULTS
There were differences among the five studies with regard to age at birth, parity, social class, and sex of the child (Table 2) . Pregnancies occurred at younger age in Germany and at older age in the Rotterdam study. There were more nulliparous women in the Dutch Epilepsy Institutes and in Germany. There were fewer skilled manual laborers in the Rotterdam study.
The distribution of the different AED regimens for each center, with the percentages of MCA for each regi men, is shown in Table 3 . Prescription regimens differed between the centers. In the Rotterdam study and the Dutch Institutes of Epilepsy study, there was a tendency toward more frequent prescription of carbamazepine (CBZ), valproate (VPA), and combination therapies, whereas phenytoin (PHT) and phenobarbital (PB) were prescribed less frequently than in the other studies. In Berlin and Magdeburg, PHT and primidone (PRM) were prescribed more often than CBZ and VPA. In Helsinki, the most frequently prescribed drugs were PHT and CBZ. The risk of MCA also differed significantly among centers. Significantly more MCA were detected in Berlin (16%) and Magdeburg (14%) than in the other centers (Table 3) .
We first compared the risks of MCA in AED-exposed 
Social class, n (%) Academic degree 3 (2) 3 (2) 15 (14) 17 (6) ----------White collar 41 (21) 29 (19) 33 (31) 102 (33) ----------Skilled manual 104 (54) 106 (67) 45 (43) 88 (29) ----------Unskilled manual 39 (20) 18 (11) 13 (12) 37 (12) ---------- 
AED, antiepileptic drug, "In all, 150 exposed and 116 nonexposed pregnancies were derived from Berlin; 42 exposed and 42 non exposed pregnancies were derived from Magdeburg, b Miscarriage; no sex determination.
pregnancies with those in matched control pregnancies, using the data from the studies from Berlin and Magde burg (Table 4) . Overall, we noted a significantly in creased risk of MCA in children of mothers with epi lepsy treated with AEDs during pregnancy as compared with children of healthy controls (RR 2.3, 95% Cl 1.2-4.7). Moreover, the risk of MCA was significantly in creased in children of women treated with CBZ (RR 4.9, 95% Cl 1.3-18.0) and in children exposed to VPA (RR 4.9, 95% Cl 1.6-15.0). Most other therapies also showed an increased RR, although it was not significant. How ever, the number of women treated with these AEDs was very small, in particular the number treated with PB and with most polytherapy regimens. When adjustment was made for maternal age, sex of the child, social class or parity of the mother, or type of maternal epilepsy in our multiple logistic regression analysis, none of the RR shown in Table 4 changed materially (data not shown in Table 4 ). Second, using the data of all centers, we compared the risks of MCA between the different drug regimens. We first calculated the risk of MCA in the different AED regimens, using all AED-exposed pregnancies pooled from all five centers (Table 5 ). The AED (monotherapy) associated with the lowest percentage of MCA (i.e., PHT) was used as a reference for comparisons with other AED regimens. In the crude overall analysis, there were no significant differences in RR of MCA between the different monotherapy AED regimens. In children of mothers treated with VPA monotherapy, however, the absolute risk of neural tube defects was 3.8% as com pared with 1.0% in those receiving CBZ monotherapy and 0% in those receiving other monotherapy regimens. For the polytherapies studied, only the combinations of PB and ethosuximide (ESM) (RR 9.8, 95% Cl 1.4-67.3; n = 5) and PHT, PB, CBZ, and VPA (RR 11.0, 95% Cl 2.1-57.6; n = 7) were shown to pose a significantly in creased risk of MCA as compared with PHT mono therapy, but very few women received these drug com binations. When adjustment was made for confounders such as type of epilepsy (Table 5) , study center, and socioeconomic status, only study center influenced the effects of the drug regimens (data not shown in Table 5 ). When adjustment was m ade for study center, the risks of MCA for the offspring of women treated with VPA (RR 3.7, 95% Cl 1.2-11.8), CBZ (RR 2.8, 95% Cl 1.1-7.3), and PB (RR 4.2, 95% C l 1.0-18.6) monotherapy were significantly increased. An increased risk of MCA in offspring of women treated with VPA was evident in all but the Helsinki study, in which VPA was not prescribed in monotherapy. For the other AED regimens, there was no evidence of confounding by study center. We did not find significant evidence of an association between any type of epilepsy and the risk of MCA in the offspring.
Finally, we evaluated the possibility of a dosedependent association (Fig. 1) (14) 10/106 (9) 22/305 (7) 46/618 (7) 108/1,221 (9) MCA, major congenital abnormalities; AED, antiepileptic drug; CBZ, carbamazepine; ESM, ethosuximide; PB, phénobarbital; PHT, phenytoin; PRM, primidone; VPA, valproate; CZP, clonazepam.
" Numbers are malformed/total exposed.
ries, we did not adjust these analyses for study center, maternal age, sex of the child, social class, parity of the mother, or maternal epilepsy. Among women treated with VPA offspring of women receiving VPA >1,000 mg/day had a significant increase in risk of MCA as compared with those of women receiving <600 mg/day (RR 6.8, 95% Cl 1.4-32.7). The MCA detected in the offspring of women receiving VPA 5*1,000 mg/day were spina bifida with or without hydrocephalus (n = 5 ; 28%); ventricular septal defect (n = 1 , 6%); tetralogy of Fallot (n = I, 6%); atrial septal defect (n = 1, 6%); craniosynostosis (n = 1 , 6%); a combination of meningo myelocele, microcephaly, and inguinal hernia (n = 1 , 6%); and a combination of aplasia of the first rib and hypersegmentation of the manubrium sterni (n = 1 , 6%). PB monotherapy also showed a trend for increased risk of MCA with increasing dose, but the differences were not significant. Malformations occurring twice or more are summarized in Tables 6 and 7 .
DISCUSSION
Our findings show an overall increased risk of MCA in children of mothers with epilepsy treated with AEDs during pregnancy as compared with children of healthy controls. The most pronounced increase in risk was that for children exposed in utero to VPA or CBZ mono therapy. Comparison of different AED regimens re ceived during pregnancy showed that risk of MCA was significantly increased for the rare combination of PB and ESM and the combination of PHT, PB, CBZ, and VPA. In an analysis adjusted for study center, this risk was also significantly increased for CBZ, PB, and VPA in monotherapy. The risk associated with VPA mono therapy appeared to be dose dependent. The offspring of mothers treated with >1,000 mg/day VPA are at in creased risk, in particular of neural tube defects. The risk associated with PB also appeared to be dose dependent.
Because our findings are based on nonrandomized studies, biases may have occurred. In none of the studies pooled were pediatricians or other investigators assess ing the presence of MCA blinded to the exposure status of the offspring. Furthermore, in this reanalysis, the data were pooled from studies that differed considerably in One case with congenital megacolon. n One case with chylothorax and persistent fetal circulation, methods used, including diagnosis and ascertainment of elusion of stillbirths and neonatal deaths in the Magdepatients. For the reanalysis, we obtained the raw data burg study. That study was relatively small (n = 42), from the individual centers and standardized the criteria and the effect of the exclusion of stillbirths and neonatal for MCA. However, we could not adjust for the nonindeaths on the risk estimates is therefore probably limited. Inguinal hernia
Congenital heart defect
Hip luxation Spina bifida occulta/aperta and/or 2 1
Abbreviations as in Table 3 9, 1997 Furthermore, in the Magdeburg group, no pregnancies had to be excluded because of stillbirth or neonatal death during the study period.
Centers differed with respect to medication prescrip tion and risks of MCA. Differences in risk of MCA may be explained in part by differences among centers in diagnostic procedures used. Because such differences may confound the analysis, we adjusted for study center in the pooled analysis and studied the association be tween AEDs and MCA (according to the standardized criteria) also within each study center. A higher risk of MCA for children exposed to VP A was detected consis tently in all centers that studied VPA, although the risk was not significant in the individual centers, most likely due to the small number of pregnancies exposed. If the association would be due to bias, this must have occurred similarly in all studies, which is plausible only in the case of confounding by indication. Confounding by indication implies that certain types of epilepsy that directly in crease the risk of MCA, may require treatment with cer tain AEDs, leading to a spurious association between the AEDs and the risk of MCA. Indeed, there was evidence of a relation between the type of epilepsy and the pre scription of AEDs in the present study. Patients with generalized epilepsy more often were prescribed VPA, ESM, PB, or PRM monotherapy and the combinations of VPA and PB, PRM, and CBZ or VPA and ESM. Patients with partial epilepsy more often received CBZ mono therapy or the combinations of CBZ and PHT, CBZ and VPA, 01* CBZ and clonazepam. Although it is difficult to exclude confounding by indication in an observational study, we noted no significant evidence of an association between any type of epilepsy and MCA, suggesting that epilepsy type is not likely to explain our results. Finally, bias may be related to the fact that multiple pregnancies in a woman were included. We therefore performed an analysis in which only the first pregnancy of a woman ascertained in the study was included. This did not change any of our conclusions.
VPA has previously been reported to pose an in creased risk of MCA. About 10 years after the introduc tion of VPA, the possibility of teratogenic effects became evident. An association with neural tube defect was ob served in mice (35, 36) . Subsequently, reports of children with neural tube defects after prenatal exposure to VPA were published (33, (37) (38) (39) (40) (41) . A risk of 1-2% was esti mated on the basis of retrospective studies (33, 38, 42) and several small prospective cohort studies (41) . The prospective study of Omtzigt et al. (23) suggested a risk as high as 6%. In the pooled analysis, the risk of neural tube defects in offspring of women treated with VPA was 3.8%. Our results, as well as those of animal experi ments (43) , suggest that VPA dose is important with regai'd to the degree of risk of neural tube defects. An association between hypospadias and VPA has also been suggested (11, 33, 44) . The current study is inconclusive with regard to this finding (n = 1). The risk of neural tube defects for offspring exposed to CBZ was 1.0%, very similar to the 0.5-1% risk reported earlier (10) .
Our reanalysis of data from five prospective studies showed that VPA is consistently associated with an in creased risk of M CA in offspring exposed in utero to VPA. An important advantage of the present study is that we were able to reanalyze data of prospective European studies using uniform criteria for the diagnosis of MCA and to determine a dose-response relationship between the occurrence of these MCA and the use of AEDs. For CBZ, we found no evidence of a dose-response relation ship, whereas risk remained NS for PB. Our study shows that in particular the offspring of women receiving 52=1,000 mg/day VPA appear to be at increased risk. Based on the risk estimates, physicians may choose not to use VPA monotherapy during pregnancy if satisfac tory seizure control can be achieved with other AEDs; if other AEDs cannot be substituted for VPA, use of daily dosages <1,000 mg/day VPA is recommended whenever results in effective seizure control. Although we pooled the data of five studies, the number of women exposed to a particular AED regimen, especially AED combina tions, remains small for a substantial number of AEDs, which results in risk estimates that are not stable. Despite the standardized case definition and gain of statistical power obtained in our reanalysis, the interpretation of our findings is still limited because of the differences in prescribing practices and case ascertainment among cen ters. Therefore, standardized single-center or multicenter studies with larger numbers of AED-exposed pregnan cies remain necessary to allow further quantification of the effect of the other AEDs in the etiology of MCA in the offspring of women with epilepsy.
We recommend performance of multicenter prospec tive and population-based studies of pregnancy outcome according to a standardized study protocol and standard ized study procedures, such as ascertainment procedures, assessment of etiological factors and outcome (including definition of outcome), inclusion and exclusion criteria, and selection of controls (if appropriate). This is espe cially relevant for the coming decades, in view of the many new AEDs currently entering the market for which no human clinical safety data are available with respect to their use during pregnancy.
